Durable Response to Atezolizumab in Extensive-Stage Small-Cell Lung Cancer Leading to 60 Months Overall Survival: A Case Report
Open Access
- 27 June 2024
- journal article
- case report
- Published by MDPI AG in Current Oncology
- Vol. 31 (7) , 3682-3689
Abstract
Small-cell lung cancer (SCLC) remains a disease with poor prognosis, particularly in extensive-stage SCLC (ES-SCLC). Current standard-of-care treatment includes chemotherapy with platinum agents and etoposide plus immunotherapy with atezolizumab or durvalumab, which has achieved a mean overall survival of 12–13 months in clinical trials. However, long-term survival in ES-SCLC, even with the addition of immunotherapy, continues to be rare. We present the case of a middle-aged male patient diagnosed with ES-SCLC who was treated with four cycles of induction chemotherapy (carboplatin and etoposide) and atezolizumab, starting maintenance atezolizumab every 21 days thereafter, and thoracic radiotherapy. After 9 months, he experienced mild disease progression and was rechallenged with six cycles of carboplatin and etoposide with continued atezolizumab. Subsequent imaging showed near-complete disease resolution which has been sustained since. He has continued on maintenance atezolizumab since diagnosis and has achieved 60 months overall survival and 44 months progression-free survival. Throughout treatment, he has maintained a high functional capacity and only experienced one immune-related adverse event. Our patient is representative of a small subset who are capable of achieving durable responses to immunotherapy and his case highlights the need for further research to elucidate the clinical and biological factors driving this response.Keywords
This publication has 20 references indexed in Scilit:
- Long-Term Survival and Stable Disease in a Patient with Extensive-Stage Small-Cell Lung Cancer after Treatment with Carboplatin, Etoposide and AtezolizumabOncology and Therapy, 2024
- Predictive biomarkers for immunotherapy response in extensive-stage SCLCJournal of Cancer Research and Clinical Oncology, 2024
- Use of radiation therapy among patients with Extensive-stage Small-cell lung cancer receiving Immunotherapy: Canadian consensus recommendationsLung Cancer, 2023
- Evolving role of immunotherapy in small cell lung cancerSeminars in Cancer Biology, 2022
- Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trialThe Lancet, 2019
- Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With NivolumabJAMA Oncology, 2019
- Novel patterns of response under immunotherapyAnnals of Oncology, 2019
- First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung CancerNew England Journal of Medicine, 2018
- Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trialThe Lancet, 2015
- Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapyEuropean Journal of Cancer and Clinical Oncology, 1987